StockData
GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31

GERON CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.20+0.03 (+2.56%)

Close on Oct 19, 2026

Market cap
$804.84K
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open$57.48M$-0.02–
Q4 FY2025
Ended Dec 31, 2025
Feb 25, 2026Before market open$48.00M$-0.05–
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open$47.20M––
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025Before market open$49.00M$-0.02–
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025Before market open$39.60M$-0.03–
Q4 FY2024
Ended Dec 31, 2024
Feb 26, 2025Before market open$47.50M$-0.04–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open$28.30M$-0.04–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open$882.00K$-0.10–
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024Before market open–––
Q3 FY2023
Ended Sep 30, 2023
Nov 2, 2023Before market open–––

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
total operating expensesfiscal year 2026$230.00M to $240.00MMaintained
RYTELO net product revenuefiscal year 2026$220.00M to $240.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Geron filed with the SEC